Cargando…

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

BACKGROUND: With previously established efficacy of aripiprazole once-monthly injectable formulation (AOM) in pre-registration randomized controlled trials, the current study was designed to evaluate its effectiveness in patients treated for schizophrenia in regular clinical settings in Canada. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustafa, Sally, Bougie, Joanna, Miguelez, Maia, Clerzius, Guerline, Rampakakis, Emmanouil, Proulx, Jean, Malla, Ashok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469112/ https://www.ncbi.nlm.nih.gov/pubmed/30991969 http://dx.doi.org/10.1186/s12888-019-2103-x

Ejemplares similares

Effectiveness and quality of life improvement in young adult schizophrenia patients treated with Abilify Maintena
por: Petrić, D., et al.
Publicado: (2023)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
por: Oluboka, Oloruntoba, et al.
Publicado: (2023)

Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study
por: Margolese, Howard C., et al.
Publicado: (2022)

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD)
por: Chokka, Pratap, et al.
Publicado: (2019)

Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
por: Schöttle, Daniel, et al.
Publicado: (2022)

Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study
por: Chokka, Pratap, et al.
Publicado: (2021)

Dual role of TRBP in HIV replication and RNA interference: viral diversion of a cellular pathway or evasion from antiviral immunity?
por: Gatignol, Anne, et al.
Publicado: (2005)

Persistent negative symptoms in schizophrenia: survey of Canadian psychiatrists
por: Lutgens, Danyael, et al.
Publicado: (2013)

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly
por: Correll, Christoph U., et al.
Publicado: (2023)

Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores
por: Ismail, Zahinoor, et al.
Publicado: (2017)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Aripiprazole: the evidence of its therapeutic impact in schizophrenia
por: Winlow, William, et al.
Publicado: (2006)

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2013)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo, Xieli, et al.
Publicado: (2015)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Efficacy and tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Andrade, Chittaranjan
Publicado: (2004)

Efficacy and Tolerability of Aripiprazole in Patients with Schizophrenia & Schizoaffective Disorders
por: Chavda, R.K., et al.
Publicado: (2004)

Retrospective Study of Japanese Patients with Schizophrenia Treated with Aripiprazole
por: Tanioka, Tetsuya, et al.
Publicado: (2012)

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2012)

Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
por: Tien, Yun, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia
por: Priya, Lakshmi, et al.
Publicado: (2021)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert, Marc, et al.
Publicado: (2015)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022)

PM293. Efficacy and Safety of Aripiprazole for Maintenance Treatment of Methamphetamine Dependence Following Methamphetamine Psychosis: A Naturalistic Retrospective Study
por: Boonlue, Tuanthon, et al.
Publicado: (2016)

Naturalist's Monthly Report
Publicado: (1811)

Naturalist's Monthly Report
Publicado: (1812)

Naturalist's Monthly Report
Publicado: (1811)

Naturalist's Monthly Report
Publicado: (1811)

Cannot write session to /tmp/vufind_sessions/sess_hjm1tcohocg5ftq5qrdi4irulp